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Abstract
Background: Artemisinin derivatives are the key active ingredients in Artemisinin combination therapies (ACTs), the most
effective therapies available for treatment of malaria. Because the raw material is extracted from plants with long growing
seasons, artemisinin is often in short supply, and fermentation would be an attractive alternative production method to
supplement the plant source. Previous work showed that high levels of amorpha-4,11-diene, an artemisinin precursor, can
be made in Escherichia coli using a heterologous mevalonate pathway derived from yeast (Saccharomyces cerevisiae),
though the reconstructed mevalonate pathway was limited at a particular enzymatic step.
Methodology/ Principal Findings: By combining improvements in the heterologous mevalonate pathway with a superior
fermentation process, commercially relevant titers were achieved in fed-batch fermentations. Yeast genes for HMG-CoA
synthase and HMG-CoA reductase (the second and third enzymes in the pathway) were replaced with equivalent genes
from Staphylococcus aureus, more than doubling production. Amorpha-4,11-diene titers were further increased by
optimizing nitrogen delivery in the fermentation process. Successful cultivation of the improved strain under carbon and
nitrogen restriction consistently yielded 90 g/L dry cell weight and an average titer of 27.4 g/L amorpha-4,11-diene.
Conclusions/ Significance: Production of.25 g/L amorpha-4,11-diene by fermentation followed by chemical conversion to
artemisinin may allow for development of a process to provide an alternative source of artemisinin to be incorporated into
ACTs.
Citation: Tsuruta H, Paddon CJ, Eng D, Lenihan JR, Horning T, et al. (2009) High-Level Production of Amorpha-4,11-Diene, a Precursor of the Antimalarial Agent
Artemisinin, in Escherichia coli. PLoS ONE 4(2): e4489. doi:10.1371/journal.pone.0004489
Editor: Aric Gregson, University of California Los Angeles, United States of America
Received November 23, 2008; Accepted December 14, 2008; Published February 16, 2009
Copyright:  2009 Tsuruta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was conducted under the sponsorship of the Institute for OneWorld Health through generous support of the Bill & Melinda Gates
Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: All authors are shareholders or hold share options in Amyris Biotechnologies.
* E-mail: Paddon@amyris.com
¤ Current address: DuPont Central Research & Development, Experimental Station E328/345B, Wilmington, Delaware, United States of America
Introduction
Malaria causes more than one million deaths annually, with the
highest mortality in children younger than five years of age [1].
There are an estimated 350–500 million clinical malaria episodes
annually caused by the parasites Plasmodium falciparum and P. vivax.
The most virulent form of malaria is caused by P. falciparum which
has become resistant to almost all currently used drug therapies
[2,3]. An exception to the pattern of clinical drug resistance seen
with older antimalarial drugs is the class of drugs known as
‘artemisinin-based combination therapies’ (ACTs). Artemisinin, a
sesquiterpene lactone peroxide with potent antimalarial properties,
is extracted from the shrub Artemisia annua and combined with one
or more other antimalarial drugs to produce ACTs. In 2005 ACTs
were recommended for the first-line treatment of uncom-
plicated falciparum malaria by the World Health Organization
(WHO) [3]. Following the WHO recommendation, the price of
artemisinin has fluctuated greatly and access to ACTs is still limited
in many malaria-endemic countries [4]. Yields of artemisinin from
A. annua are such that a substantial increase in the amount of plant
cultivated would be needed to satisfy the forecasted global demand
for artemisinin [5]. New methods for increasing the artemisinin
supply would be valuable to stabilize the supply chain and ultimately
to increase access to ACTs in developing countries. Chemical
synthesis of artemisinin is not practical due to its complexity and low
yield [4]. An alternative to total chemical synthesis of artemisinin is
the reconstruction of its biosynthetic pathway in microbes leading to
the production of precursor molecules that can be converted to
artemisinin with relatively few chemical manipulations. Develop-
ment of a semi-synthetic microbial process for the production of
artemisinin would allow for a consistent, second source of the drug
to supplement cultivation of A. annua.
Historically, heterologous production of small molecules has been
hampered by the challenges in expressing complex functional
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pathways for the production of the non-native molecules. New tools in
rapid gene synthesis and metabolite analysis have promoted the field
of synthetic biology, which promises advances in pathway re-
construction, and strives toward pathway and genome optimization.
Recent success in reconstituting heterologous pathways in microor-
ganisms for high-level production of small molecules has demonstrat-
ed the feasibility of achieving titers in the g/L range. Examples include
production of polyketides such as 6-deoxyerythronolide B [6] and
isoprenoids such as amorpha-4,11-diene [7] and lycopene [8] in
Escherichia coli. Our work focuses on improving heterologous
production of the artemisinin precursor amorpha-4,11-diene, which
can be converted to artemisinin via chemical transformation.
Recently, the expression of a synthetic amorpha-4,11-diene
synthase gene along with the mevalonate isoprenoid pathway native
to S. cerevisiae was engineered in E. coli for the production of
amorpha-4,11-diene (Figure 1) [9]. Production was increased with
the use of a two-phase partitioning bioreactor which captures the
product in the organic phase [7]. In this work, we present
improvements in amorpha-4,11-diene production in E. coli by
further strain engineering and fermentation process development.
In the original heterologous mevalonate pathway, two key genes
(HMG-CoA synthase (HMGS: ERG13, Genbank GeneID: 854913)
and the catalytic domain of HMG-CoA reductase (tHMGR:
HMG1, Genbank GeneID: 854900)) were derived from yeast [9]. It
was subsequently demonstrated that the activity of tHMGR is
insufficient to balance flux in the heterologous pathway leading to a
pathway bottleneck [10]. In the current work HMGS and tHMGR
were replaced with more active enzymes from Staphylococcus aureus,
doubling amorpha-4,11-diene production. Amorpha-4,11-diene
producing E. coli strains were grown in a defined, glucose restricted
fed-batch process which achieved cell densities of 90 g/L dry cell
weight. Titers were further improved in this process by simulta-
neously restricting ammonia and carbon. Nitrogen consumption
rates depended on the components of the pathway that were
expressed, thus the process was modified to accommodate the high
production strain containing the modified mevalonate pathway. An
amorpha-4,11-diene titer of greater than 25 g/L was achieved in a
robust and reproducible fermentation process.
Results
Glucose restricted, high cell density bioprocess
Newman et al. [7] demonstrated production of 0.5 g/L
amorpha-4,11-diene in low density fermentations from E. coli
strain W3110 transformed with plasmids pMevT, pMBIS and
pADS [9]. We introduced these plasmids into E. coli DH1 [11] to
generate strain B32 (Tables 1 and 2). DH1 was chosen as a host
strain since the metabolic burden of plasmid presence has been
previously characterized [12] and the limited engineering of this
strain suggested that it would be a robust host. All subsequently
described plasmids were transformed into E. coli DH1. To achieve
greater volumetric productivity than Newman et al. [7], a high-
density, glucose-restricted fed-batch fermentation process was
developed with ammonia maintained between 30–60 mM until
100 hours (Figure 2a). The sole source of nitrogen for this process
was ammonia, which was provided as ammonium hydroxide for
pH correction, and ammonium sulfate in the batch and feed
media. The initial glucose concentration of 15 g/L was exhausted
within 19 hours, at which time an exponential glucose feed with
6 hour doubling time was initiated. Production of amorpha-4,11-
diene was initiated with the addition of isopropyl-b-D-1-thioga-
lactopyranoside (IPTG) at an OD600 of ,30 (20 hours after
inoculation). The exponential glucose feed continued until a
maximum rate of 31 g/h was achieved, at which point the feed
was reduced to 11.7 g/h (3/8 of the maximum) and held constant.
Maximum cell density was attained 100 hours after inoculation at
an OD600 of 260 and the corresponding titer was measured at
6.5 g/L amorpha-4,11-diene (Figure 2b). With this restricted
glucose feed process, known as process A, the amount of
acetate generated from glycolysis remained close to zero until
100 hours (Figure 2b). Process A, and all processes described
below, were run until levels of glucose, acetate, and ammonia were
elevated.
Glucose and ammonia restriction at high cell density
To test the effect of nitrogen restriction on cell growth and
production of amorpha-4,11-diene, process A was modified
whereby the ammonium sulfate was left out of the feed (process
B). The ammonia in the medium was allowed to decrease to zero
though nitrogen flow into the bioreactor was still positive due to
base addition. The carbon consumption in process B was similar to
that of process A (data not shown). Once the initial glucose was
depleted, the glucose concentration was maintained at zero, thus
preventing any accumulation of acetate in the culture (Figure 3b).
Ammonium sulfate in the batch medium was utilized in the first
40 hours and the amount of ammonium hydroxide added to correct
the pH thereafter did not result in ammonia accumulation until
95 hours (Figure 3b) while supporting maximum cell density of 235
Figure 1. Depiction of the heterologous mevalonate pathway expressed in E. coli to produce amorpha-4,11-diene. Genes in blue
arrows are derived from E. coli, those in brown arrows from yeast, and ADS in red from A. annua. pMevT, pMBIS and pADS indicate the arrangement
of genes on expression plasmids. Gene names and the enzymes they encode: atoB, acetoacetyl-CoA thiolase; ERG13, HMG-CoA synthase; tHMG1,
truncated HMG-CoA reductase; ERG12, mevalonate kinase; ERG8, phosphomevalonate kinase; MVD1, mevalonate pyrophosphate decarboxylase; idi,
IPP isomerase; ispA, farnesyl pyrophosphate synthase. Pathway intermediates: Ac-CoA, acetyl-CoA; AA-CoA, acetoacetyl-CoA; HMG-CoA,
hydroxymethylglutaryl-CoA; Mev-P, mevalonate 5-phosphate; Mev-PP, mevalonate pyrophosphate; IPP, isopentenyl pyrophosphate; DMAPP,
dimethylallyl pyrophosphate; FDP, farnesyl pyrophosphate; ADS, amorphadiene synthase.
doi:10.1371/journal.pone.0004489.g001
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OD600 (Figure 3a). Similar cell growth between processes A and B
confirmed sufficient supply of nitrogen from the base to build cell
mass in process B despite the fact that the measured ammonia in the
culture was zero. The difference in amorpha-4,11-diene production
between the two runs was evident after 50 hours where the
production profiles diverged (Figure 3a). This correlated well with
the ammonia concentrations measured in the culture between
50 hours and 100 hours. In process A, ammonia was in excess at
40 mM whereas in process B the ammonia concentration was
negligible during most of the production period. Process B with
strain B32 achieved a peak amorpha-4,11-diene titer of 16.7 g/L at
120 hours, a 2.5-fold improvement in titer compared to process A.
Figure 2. Feed, metabolite, production and cell density for restricted glucose feed (Process A) fed-batch fermentation of E. coli
strain B32. 2a. Glucose and NH4 concentrations. 2b. Cell density, amorpha-4,11-diene production, and acetate concentration.
doi:10.1371/journal.pone.0004489.g002
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Improvements in amorpha-4,11-diene production
through strain engineering
Strain B32 (Table 1) contains a heterologous mevalonate
pathway consisting of genes derived from yeast, including a
truncated version of HMGR (tHMGR) expressing solely the C-
terminal catalytic domain, and HMGS (Figure 4, pMevT.
Table 2). Pitera et al. [10] showed that accumulation of the
pathway intermediate HMG-CoA limited flux through the
pathway and could result in growth inhibition due to the apparent
toxicity of this intermediate. An initial attempt to improve flux
through the mevalonate pathway was made by re-synthesizing the
MevT operon, which expresses the first three genes of the
mevalonate pathway, with genes codon-optimized for expression
in E. coli. The wild-type lac promoter was also replaced with the
two-fold stronger lacUV5 promoter [13], which also displays
significantly lower sensitivity to intracellular levels of cAMP,
thereby being less sensitive to glucose repression. The plasmid
bearing the codon optimized version of the MevT operon,
pAM25, is shown schematically in Figure 4 along with all top
pathway plasmids described below. Production of amorpha-4,11-
diene from strain B64 containing pAM25, pMBIS and pADS was
1.56higher than that from DH1 strain B32 [14]. Moreover, since
the design of the operon enabled more convenient DNA
manipulation, pAM25 was used as a basis for all subsequent
pathway engineering. To further alleviate the HMGR pathway
bottleneck more efficient HMGR enzymes were sought to prevent
the accumulation of HMG-CoA and increase flux through this
step in the pathway. Two HMGR enzymes from gram-positive
bacteria were investigated by replacement of yeast tHMGR
expressed in pAM25. The chosen gram-positive enzymes were
HMGR from S. aureus encoded by mvaA [15] (Genbank GeneID:
2861328), and the fused acetoacetyl-CoA thiolase /HMGR from
Enterococcus faecalis encoded by mvaE [16] (Genbank GeneID:
1200264). In the case of the reconstructed operon incorporating
mvaE, the entire codon-optimized MevT operon was replaced with
E. faecalis genes mvaS (encoding HMGS [17]; Genbank AF290092)
and mvaE (pAM34; Figure 4). The production of amorpha-4,11-
diene by strains B64 (top pathway encoded by pAM25 expressing
acetoacetyl-CoA thiolase, HMGS and HMGR from the codon-
optimized MevT operon [9]), B65 (top pathway encoded by
pAM34 expressing E. faecalis mvaE mvaS), and B66 (top pathway
encoded by pAM41 expressing acetoacetyl-CoA thiolase, HMGS,
and S. aureus mvaA), (Figure 4), pMBIS and pADS, was compared
during growth in shake flasks for 72 hours (Figure 5a). The highest
concentration of amorpha-4,11-diene (244 mg/L after 72 hours
growth) was produced by strain B66 expressing the mevalonate
pathway incorporating S. aureus mvaA, followed by B64 expressing
the codon-optimized yeast-derived [9] mevalonate pathway
(223 mg/L amorpha-4,11-diene). Strain B65 expressing E. faecalis
mvaE mvaS produced only 188 mg/L amorpha-4,11-diene. The
mevalonate pathway incorporating the S. aureus HMGR encoded
by mvaA (strain B66) was selected for further study. In view of the
superiority of the S. aureus HMGR for the production of amorpha-
4,11-diene in E. coli we wished to test the effect of substituting the
yeast HMGS with its S. aureus equivalent encoded by mvaS. This
was accomplished by site-directed mutagenesis of pAM41 to
substitute the yeast HMGS with S. aureus mvaS, generating pAM52
(Figure 4). Amorpha-4,11-diene production in shake flasks from
the resultant strain (B86, containing pAM52, pMBIS and pADS)
was compared with its progenitor strain B66 (containing pAM41,
pMBIS and pADS). Amorpha-4,11-diene production (Figure 5b)
was higher in B86 than B66, demonstrating the superiority of the
S.aureus mvaS+mvaA combination compared to the yeast HMGS+S.
aureus mvaA combination.
Development of a fermentation process to produce
25 g/L amorpha-4,11-diene
Production of amorpha-4,11-diene was compared between
strains B32 and B86 in bioreactors using process A. While growth
of the two strains was comparable, strain B86 produced 2.5-times
more amorpha-4,11-diene than B32, reaching 16.5 g/L at
150 hours (Figure 6). The ammonia concentration remained
steady between 60–80 mM in the B86 culture in this fermentation
process (Figure 7A)
To determine whether ammonia restriction is a generally
applicable approach in improving the production of amorpha-
4,11-diene in E. coli, strain B86 was tested in process B. With no
ammonium sulfate in the feed, the ammonia concentration was
undetectable at 42 hours, but only remained restricted for
Table 2. List of Plasmids.
Plasmid Description Reference
pMevT Expresses the atoB, HMGS (S. cerevisiae ERG13), and tHMGR (S. cerevisiae HMG1) genes under control of
PLAC. pACYC184 origin, Cm
r; produces mevalonate from acetyl-coenzyme A
[9]
pAM25 As pMevT, but atoB, HMGS, and tHMGR were codon-optimized for E. coli expression and expressed under control of PLAC(UV5) This work
pAM34 As pAM25, but expresses E. faecalis mvaS and mvaE This work
pAM41 As pAM25, but tHMGR replaced by S. aureus mvaA This work
pAM52 As pAM41, but HMGS replaced with S. aureus mvaS This work
pMBIS Expresses MK, PMK, MPD, idi, and ispA under control of PLAC. pBBR1 replicon, Tc
r; produces farnesyl pyrophosphate
from mevalonate.
[9]
pADS Expresses A. annua amorphadiene synthase under control of PLAC [9]
doi:10.1371/journal.pone.0004489.t002
Table 1. List of Strains.
Strain Plasmids
B32 pMevT, pMBIS, pADS
B64 pAM25, pMBIS, pADS
B65 pAM34, pMBIS, pADS
B66 pAM41, pMBIS, pADS
B86 pAM52, pMBIS, pADS
doi:10.1371/journal.pone.0004489.t001
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24 hours (Figure 7a). The subsequent accumulation of ammonia
up to 170 mM was due to ammonium hydroxide addition for pH
maintenance and also the slower ammonia consumption rate of
the strain. Strain B86 in process B produced 16.5 g/L amorpha-
4,11-diene at 140 hours, which is comparable to the production of
B86 in process A (Figure 7c) and B32 in process B. No substantial
improvement in amorpha-4, 11-diene production was observed
when ammonia was restricted for only 24 hours during the
production phase.
In view of the superior performance of strain B86 in flask
production experiments (Figure 5) and fermentation process A,
and the known limitations of the yeast-derived tHMGR [10,18],
strain B86 was chosen for further development. To extend the
period of nitrogen restriction with strain B86, the ammonia-
Figure 3. Feed, metabolite, production and cell density for restricted glucose and nitrogen feed (Process B) fed-batch fermentation
of E. coli strain B32. 3a. Comparison of cell density and amorpha-4,11-diene production in process A (glucose restricted) and process B (glucose and
nitrogen restricted) fermentations. 3b. Glucose, acetate and ammonia concentrations.
doi:10.1371/journal.pone.0004489.g003
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restricted process (process B) was modified so that ammonium
hydroxide in the base solution was reduced from 9.9 M to 4.9 M
with the addition of 1.3 M NaOH (process C). By exchanging the
concentrated ammonium hydroxide base solution at 72 h with the
dilute solution, constant nitrogen restriction was attained through
most of the production period (Figure 7a). The three processes
attained similar cell densities, although the density in process C
was somewhat reduced after 100 h (Figure 7b). Nonetheless, the
production of 29.7 g/L of amorpha-4,11-diene was achieved with
the successful restriction of ammonia in process C (Figure 7c).
Further reduction of ammonia delivery to the bioreactors by
increasing the use of NaOH for pH correction did not improve
production. Reducing the ammonia delivery below the rate that
just maintained an undetectable concentration led to accumula-
tion of acetate and lower titers (data not shown).
The process was replicated three times to determine the
production variability of strain B86 in process C. The three runs
displayed similar cell growth, consistently yielding cell densities
over 220 OD600 (equivalent to 88 g/L dry cell weight). An average
titer of 27.462.1 g/L amorpha-4,11-diene was attained from
these runs (Figure 8) which is a 50-fold improvement over the
previously reported highest titer [7].
Discussion
Production of an artemisinin precursor by fermentation
followed by an inexpensive chemical conversion to an active
anti-malarial compound is an attractive supplement to current
drug production methods. Fermentation is a controlled process,
amenable to scale-up, and a more reliable production method
than agricultural sources, which typically have planting cycles in
excess of 12–18 months [5]. The high titers of amorpha-4,11-diene
reported here are a promising step towards development of a
reliable second source for the economical production of artemi-
sinin.
Prior fermentation development on amorpha-4,11-diene pro-
ducing E. coli utilized an undefined excess carbon bioprocess [7].
We transformed the plasmids encoding the heterologous farnesyl
pyrophosphate-production pathway used previously [7,9] into a
robust strain of E. coli and showed a ten-fold increase in
production in a carbon-restricted, chemically defined process
compared to [7] (Figure 2b). Maintaining an ammonia concen-
tration at or near zero throughout much of the fermentation
further improved titers (Figure 3b).
Strain improvement was an integral component of enhancing
the production of amorpha-4,11-diene. Pitera et al. [10] showed
that buildup of HMG-CoA could be detrimental to flux through
the heterologous mevalonate pathway and can inhibit cell growth
in some situations. Kizer et al. [18] subsequently demonstrated that
buildup of HMG-CoA inhibits fatty acid biosynthesis, leading to
generalized membrane stress. It seemed likely that the yeast-
derived tHMGR, which is a truncated enzyme containing only the
C-terminal catalytic domain, was limiting flux through the
heterologous mevalonate pathway. We hence sought alternative
HMGRs that would overcome the flux limitation imposed by
tHMGR. Tabata and Hashimoto [19] described a process for the
production of mevalonate using E. coli expressing a heterologous
mevalonate pathway derived from E. faecalis that achieved
production of 47 g/L mevalonate. The E. faecalis HMGR encoded
by mvaE is part of a fused enzyme, having both acetoacetyl-CoA
Figure 4. Schematic of operons in plasmids encoding the first 3 enzymatic activities of the synthetic mevalonate pathway. ACT, E.
coli acetoacetyl-CoA thiolase (atoB); HMGS, S. cerevisiae HMG-CoA synthase (ERG13); tHMGR, truncated S. cerevisiae HMG-CoA reductase (HMG1); E.f.
mvaS, E. faecalis HMGS; E.f. mvaE, E. faecalis acetoacetyl-CoA thiolase / HMGR; S.a. mvaS, S. aureus HMG-CoA synthase; S.a. mvaA, S. aureus HMG-CoA
reductase; (c.o), codon-optimized for E. coli expression.
doi:10.1371/journal.pone.0004489.g004
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Figure 5. Production of amorpha-4,11-diene in shake-flask cultures by strains expressing different HMGR and HMGS enzymes. 5a:
Production of amorpha-4,11-diene by shake-flask cultures of strains B64, B65 and B66. B64 (pAM25, codon-optimized pMevT: blue curve), B65
(pAM34, E. faecalis mvaE mvaS: red curve), B66 (pAM41, S. aureus mvaA: green curve). 5b: Production of amorpha-4,11-diene by shake-flask cultures of
strains B66 and B86. B66 (pAM41, S. aureus mvaA green curve), B86 (pAM52, S. aureus mvaS mvaA: purple curve).
doi:10.1371/journal.pone.0004489.g005
Amorphadiene from E. coli
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thiolase and HMGR activities. The E. faecalis HMGR encoded by
mvaE has the enzymatic properties of a class II HMGR [16] but
has significantly lower Vmax than other class II HMGR enzymes
[20]. In view of the lower Vmax of E. faecalis HMGR encoded by
mvaE, we measured production of amorpha-4,11-diene in shake
flask cultures following replacement of tHMGR with either mvaE
or S. aureus HMGR encoded by mvaA [15]. We found rank order
production of amorpha-4,11-diene to be mvaA.tHMGR.mvaE
(Figure 5a). This result was surprising as HMGR enzyme assays
showed cell lysates from strain B65 expressing mvaE to contain
several-fold higher specific activity than lysates from strain B64
expressing tHMGR (data not shown). It may be that the
acetoacetyl-CoA thiolase activity of mvaE or the HMGS encoded
by E. faecalis mvaS limits flux through the mevalonate pathway,
though the production of 47 g/L mevalonate by a strain
expressing mvaE and mvaS [19] suggests that this is not the case.
In an effort to further improve production of amorpha-4,11-
diene from strain B66 (expressing S. aureus mvaA) we replaced the
yeast HMGS with S. aureus mvaS [21] resulting in a .40%
increased production in flasks from strain B86. Thus, replacement
of the yeast enzymes HMGS and HMGR with their equivalent
enzymes from S. aureus resulted in a significant increase in
amorpha-4,11-diene production from the heterologous mevalo-
nate pathway.
The titers were improved further by optimizing nitrogen
delivery in the fermentation process, so that the ammonia
concentration in the medium was maintained at undetectable
concentrations through most of the process. In microorganisms
that naturally produce secondary metabolites, such as actinomy-
cetes, high concentrations of ammonia frequently down-regulate
production [22]. Down-regulation of secondary metabolite
production in a heterologous host by ammonia [6,23] might be
expected in cases where the genes for the heterologous pathway
come from a closely related organism using similar regulatory
networks sensitive to ammonia. Production of epothilones from a
Sorangium cellulosum pathway transferred into the heterologous host
Myxococcus xanthus was very sensitive to ammonia in the medium,
though the native producer was more sensitive [23]. Similarly,
production of 6-deoxyerythronolide B was reduced in the
heterologous host E. coli by ammonia concentrations as low as
25 mM in shake flasks [6]. The sensitivity of 6-deoxyerythronolide
B production in E. coli to ammonia is difficult to explain because
gene expression in that system is induced with IPTG rather than a
native promoter [6]. Growth of E. coli is not inhibited until
ammonia concentrations reach levels .170 mM [24], ruling out
simple growth inhibition as the mechanism of ammonia sensitivity.
An explanation for the increase in production in the ammonia
restricted process is likely related to carbon flow. Glucose restricted
feeds effectively control the production of acetate in high density
fermentations by limiting the rate of cell growth [25]. However,
since the rate of amorpha-4,11-diene biosynthesis in E. coli
depends on the glucose feed to supply the metabolic precursor
acetyl-CoA, product biosynthesis rates are influenced by feed
rates. The nitrogen restriction could reduce amino acid and
protein biosynthesis in the cells and increase carbon availability for
amorpha-4,11-diene production.
Simultaneous restriction of two major nutrients in a fermenta-
tion process poses some challenges. In the event that one
component is restricted too tightly, the other might accrue in the
fermentation broth. The process here where both nitrogen and
carbon were maintained at or near zero throughout much of the
fermentation process was achieved by taking advantage of
nitrogen supply via pH control. Because much of the nitrogen
used in the process was supplied by the automatic addition of base
for pH control, it was possible to reduce nitrogen flow into the
bioreactor by diluting the ammonium hydroxide in the base feed
with sodium hydroxide. Another approach for ammonia control is
to use an ammonia gas sensing electrode. This method successfully
maintained ammonia between 10–100 mM in a S. cerevisiae process
for production of ergosterol, improving production 1.3-fold [26].
For processes where nitrogen is supplied in another form, careful
consumption measurements would be required to implement a
process with double restriction, and the same holds true for
simultaneous restriction of glucose and other nutrients such as
phosphate or iron.
The development of a strain of E. coli and an accompanying
process capable of producing over 25 g/L amorpha-4,11-diene in
fed-batch fermentation is a significant step towards the develop-
Figure 6. Cell growth and amorpha-4,11-diene production for strains B32 and B86 in process A.
doi:10.1371/journal.pone.0004489.g006
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ment of a commercial process for the semi-synthetic production of
artemisinin. Full commercialization of the described process would
require removal of antibiotic selection, for instance by integration
of the heterologous mevalonate pathway into the genome [27],
and use of an alternative induction system that did not require the
expensive inducer IPTG. The amorpha-4,11-diene produced by
fermentation could potentially be chemically oxidized to artemi-
sinic acid, which in turn can be converted to artemisinin [28].
Alternatively, oxidation of amorpha-4,11-diene to artemisinic acid
could be accomplished in vivo by expression of CYP71AV1, the
cytochrome P450 from A. annua [29,30] in an amorpha-4,11-
diene-producing E.coli strain. Chang et al. [31] demonstrated that
CYP71AV1 can be functionally expressed in E. coli with its cognate
P450 reductase, though only low amounts of artemisinic alcohol
were produced. Modifications to the N-terminal transmembrane
sequence of CYP71AV1, along with changes in expression vector,
host strain, and culture conditions, resulted in production of
105 mg/L of artemisinic acid. Subsequent development of
amorpha-4,11-diene producing E. coli expressing CYP71AV1 and
its cognate reductase has allowed a significant improvement in
production of artemisinic acid (D. Pitera, Pers. Comm.). An
alternative method of microbial production of amorpha-4,11-
diene or artemisinic acid is the use of engineered yeast
(Saccharomyces cerevisiae). Ro et al. [29] produced 153 mg/L of
amorpha-4,11-diene in yeast cultures by expression of ADS and
manipulation of the native mevalonate pathway. Expression of
CYP71AV1 in this yeast strain resulted in production of 115 mg/L
artemisinic acid. The strain described by Ro et al. [29] was
subsequently shown to be capable of producing 2.5 g/L
artemisinic acid in a novel fermentation process [32]. The work
described here, enabling the production of over 25 g/L amorpha-
4,11-diene from E. coli combined with chemical oxidation and
transformation to artemisinin is one option for the semi-synthetic
production of artemisinin, which will need to be compared for
feasibility of commercial production with a yeast process capable
of producing lower concentrations (2.5 g/L) of artemisinic acid. A
second source of artemisinin to stabilize the price and increase the
supply of ACTs for the treatment of malaria in the developing
world is highly desirable, and this work describes progress towards
an option for the provision of such an alternative supply.
Methods
Strains
E. coli DH1 was used as the isoprenoid expression strain. The B32
strain contained plasmids encoding the heterologous mevalonate
pathway previously described by Martin et al. [9]. Construction of the
E. coli codon-optimized MevT operon is described by Anthony et al.
[14]. Codon-optimized MevT (referred to as MevT66 by Anthony et
al. [14]) was ligated into EcoRI+HindIII digested pAM29 [14] to
generate pAM25. For construction of pAM34, Enterococcus faecalis mvaS
was amplified from genomic DNA of E. faecalis ATCC 700802 using
primers TATAGAATCTTAAGGAGGATATTTAGATGA-
CAATTGGGATTGATAAAATTAG and TTTGGATCCT-
TAGTTTCGATAAGAGCGAACGG with PhusionTM DNA poly-
merase (New England Biolabs; all amplifications used this enzyme
according to manufacturer’s instructions) and the following condi-
tions: 1 cycle 98uC, 30 s; 30 cycles 98uC, 30 s/ 55uC, 20 s/ 72uC,
90 s; 1 cycle 72uC, 10 m. E. faecalis mvaE was similarly amplified with
primers TATGGATCCTAAGGAGGATATTTAGATGAAAA-
CAGTAGTTATTATTGATGC and AGCTAAGCTTT-
TATTGTTTTCTTAAATCATTTAAAATAGC. Amplicons were
ligated into SmaI digested pBluescript II KS+ (Stratagene) and the
DNA sequence verified. E. faecalis mvaS and mvaE were excised from
pBluescript II KS+ with EcoRI+BamHI and BamHI+HindIII respec-
tively and the excised amplicons were ligated into EcoRI+HindIII
digested pAM29 [14] to generate pAM34. HMGR from pAM25 was
replaced with Staphylococcus aureus mvaA (HMGR) to generate pAM41.
S. aureus mvaA was amplified from genomic DNA of Staphylococcus aureus
subsp. aureus ATCC 700699D with the primers GCTACTAGTAG-
GAGGAAAACATCATGCAAAGTTTAGATAAGAATTTCCG
and GCTTCTAGACTATTGTTGTCTAATTTCTTGTAAAA
TGCG using the same reaction conditions used to amplify E. faecalis
mvaE and mvaS. The amplified mvaA fragment was digested with SpeI
and ligated into the SpeI+HincII digested pAM25 so as to create
pAM41 with the operon atoB-ERG13-mvaA. mvaS was similarly
amplified with the primers GAACTGAAGATCTAGGAGGAAAG-
CAAAATGACAATAGGTATCGACAAAATAAACT and TTGC
ATGATGTTTTCCTCCTACTAGTTACTCTGGTCTGTGAT
ATTCGCGAAC.ERG13 in the atoB-ERG13-mvaA operon of pAM41
was replaced with mvaS by the method of Geiser et al. [33] to generate
the atoB-mvaS-mvaA operon in pAM52.
Flask growth conditions and seed cultures
Seed cultures for fed-batch cultivation were prepared by
inoculating 1 mL of frozen cells (20% (v/v) glycerol) of E. coli
strain B32 or B86 into a flask containing 50 mL of M9 medium.
M9 medium contained (per L) 8 g glucose, 12.8 g Na2H-
PO4?7H2O, 3 g KH2PO4, 0.5 g NaCl, 1 g NH4Cl, 2 mmol
MgSO4, 0.1 mmol CaCl2, 0.1 mg thiamine, 100 mmol MOPS
buffer pH 7.4, 3.7 mg (NH3)6Mo7O24?4 H2O, 25 mg H3BO4,
7.1 mg CoCl2, 2.4 mg CuSO4, 16 mg MnCl2, 2.8 mg ZnSO4, and
0.28 mg FeSO4. B32 cultures also contained 5 mg/mL tetracy-
cline, 100 mg/mL carbenicillin and 34 mg/mL chloramphenicol
and B86 cultures also contained 5 mg/mL tetracycline, 100 mg/
mL carbenicillin, and 50 mg/mL kanamycin. Cultures were
incubated overnight at 37uC and 250 rpm overnight and
subcultured the following morning into the same medium
containing the same antibiotics to an OD600 of ,1.0 and allowed
to grow to an OD600 of 3–5 at 37uC and 250 rpm. The cells were
used to inoculate a 2 L bioreactor at 5% (v/v).
For shake flask production experiments 20 ml of M9 medium in
125 ml shake flasks was inoculated with frozen cells as described
above. Following overnight growth at 30uC the culture was used to
inoculate 140 ml of M9 medium containing 1 mM IPTG and
20 ml dodecane in a 500 ml flask at a 1:100 dilution. Cell growth
was monitored by OD600 while dodecane samples were removed
at intervals for measurement of amorph-4,11-diene as described
below.
Fed-batch cultivation
The process used for production of amorpha-4,11-diene was
based on the glucose process described by Korz et. al. [34]. One
liter of batch medium composed of 4.2 g KH2PO4, 15.7 g
K2HPO4?3H2O, 2 g (NH4)2SO4, 1.7 g citric acid, and 8.4 mg
EDTA was prepared and sterilized in a 2 L Applikon Bioconsole
ADI 1025 vessel at 121uC for 30 minutes. Post sterile additions for
a batch medium were prepared as concentrated stocks, filter
sterilized, and injected into the bioreactor through a septum on the
head plate. They consisted of 15 g glucose, 1.2 g MgSO4?7H2O,
4.5 mg thiamine HCl, and 10 mL of batch trace metal solution
containing 0.25 g/L CoCl2?6H2O, 1.5 g/L MnCl2?4H2O,
0.15 g/L CuCl2?2H2O, 0.3 g/L H3BO4, 0.25 g/L Na2-
MoO4?2H2O, 1.3 g/L Zn(CH3COO)2?2H2O, and 10 g/L
Fe(III)citrate hydrate. Antibiotics (5 mg/mL tetracycline,
100 mg/mL carbenicillin, and 50 mg/mL kanamycin) were added
to B86 processes for plasmid retention. For strain B32 plasmid
stability was .95% without antibiotics in the production medium
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(data not shown). Cultivation was carried out at 30uC and the pH
was adjusted at 7.0 using ammonium hydroxide. The airflow and
the initial agitation rate were set at 1 v/v/m and 700 rpm,
respectively. The dissolved oxygen tension was controlled at 40%
of saturation using an agitation cascade and oxygen enrichment.
Biospumex antifoam 200 K was used to control foam. Once the
initial glucose (15 g/L) was exhausted and the dissolved oxygen
spiked, an exponential feed with a 6 hour doubling time was
initiated. The feed solution consisted of 650 g/L glucose, 12 g/L
MgSO4?7H2O, 10.7 g/L (NH4)2SO4, 13 mg/L EDTA, and
10 mL/L of feed trace metal solution that was composed of
0.4 g/L CoCl2?6H2O, 2.35 g/L MnCl2?4H2O, 0.25 g/L
CuCl2?2H2O, 0.5 g/L H3BO4, 0.4 g/L Na2MoO4?2H2O,
1.6 g/L Zn(CH3COO)2?2H2O, and 4 g/L Fe(III)citrate hydrate.
(NH4)2SO4 was taken out from the feed for nitrogen restricted
runs. The fermenter software (BioXpert) was programmed to
calculate feed rates according to the following equation:
ms tð Þ~S0mem t{t0ð Þ
m~0:12h{1
S0~15g
where S0 is initial glucose concentration, m is specific growth rate,
and t0 is time of glucose depletion from the batch medium. After
reaching a maximum feed rate of 31 g glucose/h, the feed rate was
reduced to 11.7 g glucose/h and held constant for the remainder
of the run. The culture was induced with 1 mM IPTG at an
OD600 of 30 and 10% (v/v) dodecane was added to the culture
immediately after induction to capture amorpha-4,11-diene in the
organic phase. The pH was maintained at 7 with the automatic
addition of ammonium hydroxide and/or sodium hydroxide as
described in the results. The fed-batch fermentation process was
cultivated for 6–7 days.
Ammonia, glucose, and acetate analysis
The ammonia, glucose, and acetate concentrations were
measured off-line using Bioprofile 300 analyzer (Nova Biomedical)
according to the manufacturer’s instructions. Where the concen-
trations of the analytes were outside the range of the instrument,
samples were diluted into Nova buffer which contained per liter
6 g HEPES acid, 0.64 g LiCl, and 0.46 g LiOH.
Cell density measurements
OD600 was measured in a Genesys 10vis spectrophotometer at
600 nm. The relationship between dry cell weight and OD600 was
measured in the following manner. Samples were taken through-
out high density E. coli processes and OD600 was measured for
each sample (the OD600 measurements ranged between 0.5 and
200). To measure dry cell weight, 1.5 mL of well mixed broth was
centrifuged in weighed eppendorf tubes. The supernatants were
removed from the samples and discarded. The cell pellets were
washed once with water. The samples were centrifuged again and
the water was removed. The washed cell pellets were dried in an
oven at 80 C for at least three days. The samples were weighed,
and the tube weight subtracted. The dry cell weight was calculated
by dividing the sample weight (g) by the sample volume (0.0015 L),
and graphing the relationship. OD600 of 1 was found to be
equivalent to 0.4 g/L dry cell weight.
Amorpha-4,11-diene quantitation
The production of amorpha-4,11-diene (AD) was monitored by
gas chromatography/mass spectrometry (GC/MS), using trans-
caryophyllene (TC; Sigma Chemical Company) as an internal
Figure 7. Comparison of ammonia concentration, cell growth and amorpha-4,11-diene production in fed-batch processes A
(restricted glucose), B (restricted glucose and nitrogen) and C (restricted glucose and nitrogen with NaOH pH control) for strain
B86. 7a: Ammonium concentration. 7b: Cell growth. 7c: Production of amorpha-4,11-diene.
doi:10.1371/journal.pone.0004489.g007
Figure 8. Amorpha-4,11-diene production in triplicate fed-batch process C fermentations with strain B86.
doi:10.1371/journal.pone.0004489.g008
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standard. AD was extracted from the cell pellet by diluting 25 mL
of well mixed whole cell broth with 975 mL of methanol, followed
by mixing, and dilution of 10 mL of the methanol extract into
990 mL of ethyl acetate containing TC (10 ppm v/v). AD
standards were prepared by diluting purified AD into the same
ethyl acetate containing TC to concentrations between 0.63–
10 mg/L. The standards and ethyl acetate-extracted samples were
analyzed on an Agilent 6890N gas chromatograph equipped with
an Agilent 5975 mass spectrometer (GC/MS) in single-ion
monitoring (SIM) mode. The fragment ion, m/z 189, and the
molecular ion, m/z 204, were used to monitor AD and TC. To
expedite run times, the temperature program and column matrix
were modified to achieve optimal resolution and the shortest
overall runtime (5.43 min). A 1 mL sample was split 1:20 and was
separated using a HP-5MS column (Agilent Technologies, Inc.)
with helium as the carrier gas. The temperature program for the
analysis was follows: the column was initially held at 100uC for
0.75 min, followed by a temperature gradient of 65uC/min to a
temperature of 170uC, where the gradient was decreased to 50uC/
min until the temperature reached 300uC. The column was held
at 300uC for 1 min to elute all remaining components. Under
these conditions, TC and AD elute at 3.37 and 3.49 min
respectively.
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